ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.225
-0.06%
Bitcoin
66,671.99
0.73%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Kinnate Biopharma Inc (KNTE)

  7. Kinnate Biopharma Inc (KNTE) Noticias

KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KNTE
FechaHoraFuenteTítuloSímboloCompañía
03/04/202408:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:KNTEKinnate Biopharma Inc
19/03/202415:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
05/03/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
04/03/202416:27Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:KNTEKinnate Biopharma Inc
01/03/202407:53Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
01/03/202407:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
01/03/202407:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
01/03/202407:30GlobeNewswire Inc.Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
16/02/202416:57PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
16/02/202409:46PR Newswire (US)Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmNASDAQ:KNTEKinnate Biopharma Inc
16/02/202407:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:KNTEKinnate Biopharma Inc
16/02/202407:00GlobeNewswire Inc.Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareNASDAQ:KNTEKinnate Biopharma Inc
14/02/202408:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNTEKinnate Biopharma Inc
09/11/202315:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
09/11/202315:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
18/09/202315:10GlobeNewswire Inc.Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringNASDAQ:KNTEKinnate Biopharma Inc
08/08/202315:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
13/06/202317:33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KNTEKinnate Biopharma Inc
12/06/202315:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KNTEKinnate Biopharma Inc
01/06/202315:05GlobeNewswire Inc.Kinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesNASDAQ:KNTEKinnate Biopharma Inc
11/05/202315:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KNTEKinnate Biopharma Inc
11/05/202315:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
08/05/202316:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:KNTEKinnate Biopharma Inc
28/04/202315:18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KNTEKinnate Biopharma Inc
28/04/202315:18Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KNTEKinnate Biopharma Inc
17/04/202313:35GlobeNewswire Inc.Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway GuidanceNASDAQ:KNTEKinnate Biopharma Inc
17/04/202313:30GlobeNewswire Inc.First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant MelanomaNASDAQ:KNTEKinnate Biopharma Inc
06/04/202308:30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KNTEKinnate Biopharma Inc
17/03/202315:23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KNTEKinnate Biopharma Inc
15/03/202315:05GlobeNewswire Inc.Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:KNTE

Su Consulta Reciente

AMEX
XLF
Financial Select Sector
NASDAQ
TSLA
Tesla
COIN
SOLUSD
Solana
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
BAC
Bank of America
NYSE
NKE
Nike
NYSE
CVX
Chevron
NYSE
XOM
Exxon Mobil
NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
CCOM
OILBRENT
Brent Oil
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
CCOM
US30
US 30
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados